Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Gossamer Bio, Inc. Director's Dealing 2021

Apr 20, 2021

32603_dirs_2021-04-20_96c17c24-3cd4-477b-87b7-4d944ac74056.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Gossamer Bio, Inc. (GOSS)
CIK: 0001728117
Period of Report: 2021-04-16

Reporting Person: Peterson Caryn (EVP, Regulatory Affairs)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 64008 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $2.61 2028-05-21 Common Stock (86444.0) Direct
Stock Option (Right to Buy) $10.71 2028-12-10 Common Stock (48888.0) Direct
Stock Option (Right to Buy) $22.1 2029-03-25 Common Stock (48500.0) Direct
Stock Option (Right to Buy) $16.4 2029-12-23 Common Stock (13750.0) Direct
Stock Option (Right to Buy) $14.55 2030-02-14 Common Stock (34175.0) Direct
Stock Option (Right to Buy) $9.79 2031-02-25 Common Stock (28250.0) Direct

Footnotes

F1: Includes 54,427 restricted stock unit awards, which will vest in accordance with the terms of each award and subject to the Reporting Person's continuous service to the Issuer on each vesting date.

F2: 64,840 shares subject to the option have vested and are fully exerciseable and 1/48th of the total number of shares subject to the option vest on April 21, 2021 and the last day of each one-month period thereafter through May 21, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

F3: 28,540 shares subject to the option have vested and are fully exerciseable and 1/48th of the total number of shares subject to the option vest on May 10, 2021 and the last day of each one-month period thereafter through December 10, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

F4: 24,250 shares subject to the option have vested and are fully exerciseable and 1/48th of the total number of shares subject to the option vest on April 25, 2021 and the last day of each one-month period thereafter through March 25, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

F5: 4,296 shares subject to the option have vested and are fully exerciseable and 1/48th of the total number of shares subject to the option vest on April 23, 2021 and the last day of each one-month period thereafter through December 23, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

F6: 9,967 shares subject to the option have vested and are fully exerciseable and 1/48th of the total number of shares subject to the option vest on May 14, 2021 and the last day of each one-month period thereafter through February 14, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

F7: 25% of the total number of shares subject to the option will vest on February 25, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.